Literature DB >> 7691401

Role for membrane and secreted insulin-like growth factor-binding protein-2 in the regulation of insulin-like growth factor action in lung tumors.

J G Reeve1, J Morgan, J Schwander, N M Bleehen.   

Abstract

The insulin-like growth factors (IGFs) have been implicated in the autocrine and/or paracrine growth of a number of tumor types, including lung tumors. Importantly, insulin-like growth factor-binding proteins (IGFBPs), which both enhance and inhibit the physiological and biological actions of the IGFs, have been shown to be secreted in vitro by a wide range of tumors. In particular, IGFBP-2 is frequently produced by human tumor cells, suggesting that this protein may be an important determinant of IGF action in tumors. In the present study, we investigated IGFBP-2 effects in lung tumor cells by examining the influence of IGFBP-2 on IGF-receptor interaction and the biological actions of IGF-I and IGF-II. Affinity cross-linking studies demonstrated expression of type-I and type-II IGF receptors on small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) cells and the presence of abundant membrane-associated IGFBP in SCLC cells but not in NSCLC cells. An antiserum specific for IGFBP-2 was used in immunoprecipitation and immunoblotting studies which demonstrated that the membrane-associated IGFBP identified by affinity cross-linking in SCLC cells is IGFBP-2. In NSCLC cells, both IGF-I and IGF-II bound predominantly to IGF-I receptors, whereas in SCLC cells binding was principally to surface-associated IGFBP-2. SCLC cells failed to respond to IGF-I and -II stimulation in a DNA synthesis assay. For NSCLC cells, IGF-II was a more potent stimulator of DNA synthesis than IGF-I. Soluble IGFBP-2 inhibited the binding of radiolabeled IGF-I and -II to both SCLC and NSCLC cells in a concentration-dependent manner and inhibited IGF-stimulated DNA synthesis in NSCLC cells. These observations indicate that both soluble and membrane-associated IGFBP-2 compete with IGF receptors for ligand binding and, thus, are likely to be important determinants of IGF responsiveness. The findings of the present study also indicate that the type-I receptor on NSCLC cells contains a high-affinity binding site for IGF-II which presumably mediates the biological effects of IGF-II in these cells, thereby implicating IGF-II in the autocrine/paracrine growth of NSCLC.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7691401

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  18 in total

1.  Is insulin-like growth factor binding protein 2 associated with metastasis in lung cancer?

Authors:  Qinghua Hu; Lingjin Huang; Xuyuan Kuang; Heng Zhang; Guoqiang Ling; Xuliang Chen; Kejiang Li; Zhenghao Deng; Jianhua Zhou
Journal:  Clin Exp Metastasis       Date:  2014-03-29       Impact factor: 5.150

2.  Differential expression of IGF components and insulin receptor isoforms in human seminoma versus normal testicular tissue.

Authors:  Tanja Pascale Neuvians; Isabella Gashaw; Andrea Hasenfus; Axel Hacherhäcker; Elke Winterhager; Rainer Grobholz
Journal:  Neoplasia       Date:  2005-05       Impact factor: 5.715

3.  Type I insulin-like growth factor receptor induces pulmonary tumorigenesis.

Authors:  Nicolle M Linnerth; Megan D Siwicky; Craig I Campbell; Katrina L M Watson; James J Petrik; Jeffrey A Whitsett; Roger A Moorehead
Journal:  Neoplasia       Date:  2009-07       Impact factor: 5.715

4.  Role of insulin-like growth factor binding protein 2 in lung adenocarcinoma: IGF-independent antiapoptotic effect via caspase-3.

Authors:  Toshiro Migita; Tadahito Narita; Reimi Asaka; Erika Miyagi; Hiroko Nagano; Kimie Nomura; Masaaki Matsuura; Yukitoshi Satoh; Sakae Okumura; Ken Nakagawa; Hiroyuki Seimiya; Yuichi Ishikawa
Journal:  Am J Pathol       Date:  2010-02-11       Impact factor: 4.307

5.  Reduction in receptors for bombesin and epidermal growth factor in xenografts of human small-cell lung cancer after treatment with bombesin antagonist RC-3095.

Authors:  G Halmos; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-04       Impact factor: 11.205

6.  Insulin-like growth factor binding protein 7 mediates glioma cell growth and migration.

Authors:  Wei Jiang; Cunli Xiang; Simona Cazacu; Chaya Brodie; Tom Mikkelsen
Journal:  Neoplasia       Date:  2008-12       Impact factor: 5.715

Review 7.  Genetic changes in small cell lung carcinoma.

Authors:  Edurne Arriola; Israel Cañadas; Montse Arumí; Federico Rojo; Ana Rovira; Joan Albanell
Journal:  Clin Transl Oncol       Date:  2008-04       Impact factor: 3.405

8.  Neuroendocrine cancer-specific up-regulating mechanism of insulin-like growth factor binding protein-2 in small cell lung cancer.

Authors:  Takuya Yazawa; Hanako Sato; Hiroaki Shimoyamada; Koji Okudela; Tetsukan Woo; Michihiko Tajiri; Takashi Ogura; Nobuo Ogawa; Takehisa Suzuki; Hideaki Mitsui; Jun Ishii; Chie Miyata; Masashi Sakaeda; Kazuya Goto; Korehito Kashiwagi; Munetaka Masuda; Takashi Takahashi; Hitoshi Kitamura
Journal:  Am J Pathol       Date:  2009-08-13       Impact factor: 4.307

9.  Expression patterns of insulin-like growth factor system members and their correlations with growth and carcass traits in Landrace and Lantang pigs during postnatal development.

Authors:  Zicong Li; Zhenfang Wu; Guangcai Ren; Yunxiang Zhao; Dewu Liu
Journal:  Mol Biol Rep       Date:  2012-12-27       Impact factor: 2.316

10.  ERK phosphorylation is predictive of resistance to IGF-1R inhibition in small cell lung cancer.

Authors:  Rebekah L Zinn; Eric E Gardner; Luigi Marchionni; Sara C Murphy; Irina Dobromilskaya; Christine L Hann; Charles M Rudin
Journal:  Mol Cancer Ther       Date:  2013-03-20       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.